论文信息 - Reporting of Drug Reaction with Eosinophilia and Systemic Symptoms from 2002-2019 in the FDA Adverse Event Reporting System (FAERS). - 字舞流文

Reporting of Drug Reaction with Eosinophilia and Systemic Symptoms from 2002-2019 in the FDA Adverse Event Reporting System (FAERS).

E. Phillips | C. Stone | R. Yu | S. Bluestein

[1] E. Phillips,et al. Emerging Causes of Drug-Induced Anaphylaxis: A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event Reporting System (FAERS). , 2020, The journal of allergy and clinical immunology. In practice.

[2] I. James,et al. HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms. , 2019, The Journal of allergy and clinical immunology.

[3] M. Pirmohamed,et al. Controversies in drug allergy: Testing for delayed reactions. , 2019, The Journal of allergy and clinical immunology.

[4] Q. Xing,et al. Clinical, Viral and Genetic Characteristics of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) in Shanghai, China. , 2018, Acta dermato-venereologica.

[5] H. Turki,et al. HLA-A*31:01 and carbamazepine-induced DRESS syndrom in a sample of North African population , 2017, Seizure.

[6] C. Chu,et al. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): An Interplay among Drugs, Viruses, and Immune System , 2017, International journal of molecular sciences.

[7] C. Sukasem,et al. HLA-B*58:01 for Allopurinol-Induced Cutaneous Adverse Drug Reactions: Implication for Clinical Interpretation in Thailand , 2016, Front. Pharmacol..

[8] J. Roujeau,et al. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). , 1996, Seminars in cutaneous medicine and surgery.